1. Application of Biologics in IBD:

3. Program Overview

4. Treating IBD: Sprint or Marathon

5. Why Use a Biologic Therapy?

6. Treat-to-Target Concept in IBD

7. Mucosal Healing

8. Mucosal Healing (cont)

9. Benefits of Tight Control Management: The CALM Study

10. Advanced Therapy in UC, Including Biololgics

11. Biologic Therapy in CD

12. Considerations When Choosing Between Ustekinumab and Vedolizumab

13. Vedolizumab vs Anti-TNF Therapy in CD

14. Efficacy of Ustekinumab vs Placebo in CD

15. Safety of Anti-TNF Therapy in CD

16. Safety of Novel Biologic Agents in CD

17. Role of Biosimilars in CD

18. Long-Term Outcomes With CD Therapy

19. Immunogenicity of Biologic Therapy

20. Real-World Data on Vedolizumab: Persistence

21. Real-World Data on Vedolizumab: Mucosal Healing

22. Likely Future Developments in IBD

23. Choosing Biologics -- Key Messages

24. Summary

25. Abbreviations

26. Abbreviations (cont)